Icobrain
by Icometrix NV
· Based in Belgium →
— Brain Imaging AI That Transforms Neurology Care
Contact for pricing
Regulatory Status Disclosed
Overview
Icobrain is an AI-powered software developed by Icometrix NV that provides quantitative analysis of brain MRI and CT scans. It is designed to assist radiologists and neurologists in the diagnosis, monitoring, and treatment assessment of various neurological conditions. The platform automates the identification, labeling, and volumetric quantification of segmentable brain structures and abnormalities, comparing them to age- and sex-matched normative data. Icobrain offers disease-specific modules, including solutions for multiple sclerosis (icobrain ms), dementia and Alzheimer’s disease (icobrain dm), and the detection and grading of amyloid-related imaging abnormalities (ARIA) (icobrain aria). The software integrates seamlessly into existing hospital workflows, generating detailed reports and color-coded visualizations to provide objective and reproducible insights into disease progression and treatment response.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered brain MRI and CT analysis
- Automatic labeling and volumetric quantification of brain structures
- Detection and quantification of lesions and brain atrophy
- Comparison to age- and sex-matched normative data
- Longitudinal monitoring of brain volume changes
- Disease-specific reports (MS, dementia, TBI, stroke, epilepsy, ARIA)
- Cloud-based solution with on-premise data transfer (icobridge)
- Computer-assisted detection and diagnosis (CADe/CADx)
- Pseudonymization and encryption of patient data
- FDA-cleared and CE-marked insights
Use Cases
- Diagnosis and monitoring of multiple sclerosis
- Differential diagnosis and monitoring of atrophy in dementia and Alzheimer's disease
- Detection and grading of Amyloid-Related Imaging Abnormalities (ARIA)
- Quantification of traumatic brain injury and tracking structural changes
- Supporting differential diagnosis of epilepsy
- Monitoring stroke and brain tumors
Details
| Category | Neurology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing — Starting at $100,000+ per project; hourly rates $120–$180 |
| Deployment | Cloud-based with on-premise data transfer via icobridge |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Icobrain has multiple FDA 510(k) clearances. Notably, icobrain aria received FDA clearance on November 7, 2024, as the first AI software approved for detecting, measuring, and grading amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Icobrain MR also has FDA clearance for automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images. |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurology, Radiology |
What the Web Says
Icobrain is an AI-powered software developed by Icometrix that provides quantitative analysis of brain MRI and CT scans for various neurological conditions, including multiple sclerosis (MS), dementia, traumatic brain injury (TBI), stroke, and epilepsy. It aims to assist radiologists and neurologists in detecting and tracking disease progression, assessing treatment response, and improving diagnostic accuracy. The software generates structured reports with annotated images and compares measurements to age- and sex-matched normative data. Icobrain has received FDA clearance for detecting and grading amyloid-related imaging abnormalities (ARIA) in Alzheimer's treatments.
Overall: PositiveStrengths
- Provides AI-based quantitative analysis of brain MRI and CT scans, offering objective data.
- Aids in early detection and tracking of disease progression in conditions like MS and dementia.
- Improves diagnostic accuracy and consistency, potentially bridging the gap between expert and non-expert radiologists.
- Reduces staff reporting time and enhances the quality of radiological reports.
- Facilitates better communication and collaboration between radiology and neurology teams.
- FDA-cleared for specific applications like detecting ARIA in Alzheimer's treatments, enhancing patient safety.
Limitations
- Evidence is limited in quantity and quality, primarily assessing technical validity rather than patient benefits.
- Can only be used in addition to current practice, not as a standalone diagnostic tool.
- Cost can be substantial, ranging from u00a330,000 to u00a360,000 per year, in addition to standard care.
- Some Reddit users express concerns about the accuracy of AI in detecting subtle anatomical differences versus lesions and privacy when uploading MRI data to online tools.
- Real-time collection and analysis of evidence for broad clinical adoption/implementation is still needed for some applications like TBI.
- One Reddit user mentioned their insurance did not cover the additional cost of an Icobrain scan.
Based on reviews from: Elion, YouTube (icoMetrixLeuven), NICE, Icometrix, Multiple Sclerosis News Today, Reddit, Moberg Analytics, Shields Health, Blackford Analysis
Last updated: 2026-07-20
Ratings & Reviews
Rate Icobrain
Press & Coverage
NeurologyLive
FDA Clears Icobrain Aria, First AI Tool for Safer ARIA Detection in Alzheimer Treatment
The FDA has cleared icobrain aria, the first AI software approved for automated detection and severity grading of amyloid-related imaging abnormalities (ARIA), a potential side effect of new Alzheimer's disease therapies. This tool aims to improve safety monitoring for patients and bridge the gap between expert and non-expert radiologists.
2024-11
icometrix
Market approval for icobrain aria - icometrix
Icometrix announced market approval for icobrain aria in Europe, Switzerland, Israel, the United Kingdom, and Japan, making it the first market-approved solution for monitoring ARIA in Alzheimer's disease. This milestone aims to ensure safer and more effective treatment of Alzheimer's by providing tools for careful monitoring.
2024-09
AuntMinnieEurope
Icometrix gains EU approval for ARIA monitoring AI software - AuntMinnieEurope
Icometrix has received approval to market its icobrain aria software in Europe, Israel, Japan, Switzerland, and the U.K. The software is designed for automated quantification and severity scoring of amyloid-related imaging abnormalities (ARIA), which are important for monitoring patients on amyloid beta-directed monoclonal antibodies for Alzheimer's disease.
2024-09
Baptist Health
Baptist Health First In Arkansas To Utilize Cutting-Edge icometrix AI Technology for Neuroradiology
Baptist Health is the first healthcare organization in Arkansas to implement icometrix's icobrain AI technology to enhance neuroradiology services. This software analyzes brain MRI scans to detect and monitor neurological conditions like multiple sclerosis, dementia, and traumatic brain injury with greater precision.
2024-10
icometrix
The first AI-driven MRI solution for safer Alzheimer's treatment - icometrix
On November 7th, 2024, the FDA granted icometrix clearance for icobrain aria, the first AI software approved for detecting, measuring, and grading ARIA, a side effect of new amyloid-targeting therapies for Alzheimer's disease. This clearance is a significant step in making new Alzheimer's treatments safer and more accessible.
2025-05
GE HealthCare
GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions
GE HealthCare announced its intent to acquire icometrix to integrate the icobrain platform with its MRI systems, aiming to strengthen its neurology portfolio with brain MRI assessment solutions. This acquisition aligns with GE HealthCare's precision care strategy and focuses on enhancing clinical decision support for neurological disorders.
2025-09
icometrix
MSAA and icometrix Partner to Expand MRI Access and Equity in MS Care
The Multiple Sclerosis Association of America (MSAA) and icometrix (now a GE HealthCare company) announced a partnership to expand the MRI Access Program, incorporating advanced AI-powered MRI analysis through icobrain ms technology. This collaboration aims to improve the detection and tracking of disease progression and evaluate treatment effectiveness in MS care.
2026-06
icometrix
icobrain receives ACR Transparent AI badge: advancing trusted AI in neuroimaging
Icometrix announced that icobrain has been awarded the ACR Transparent AI badge by the American College of Radiology, recognizing its commitment to transparent, clinically validated, and trusted AI in neuroimaging. This badge signifies that icobrain meets rigorous standards for openness, accountability, and safety in clinical use.
2025-09
Frequently Asked Questions
Icobrain is an AI-powered neuroimaging software that provides quantitative insights from MRI and CT scans to assist in diagnosing and monitoring various neurological conditions, such as multiple sclerosis, dementia, and epilepsy. It integrates seamlessly into existing radiology workflows, generating automated reports with volumetric and lesion quantification, color-coded segmentations, and pre-populated templates to streamline clinical decision-making and communication.
Icobrain is FDA-cleared and CE-marked (MDR-certified), indicating its compliance with stringent medical device regulations. The developer, icometrix, is ISO13485 and ISO27001 certified, and adheres to GDPR and HIPAA regulations, ensuring patient data privacy and security through measures like pseudonymization of DICOM files before data transfer.
While highly accurate, Icobrain's AI has shown lower specificity rates for certain amyloid-related imaging abnormalities (ARIA) compared to unassisted radiologist reads in some studies. Additionally, the software was not trained to segment macrohemorrhages, and a Medicare contractor has raised concerns about the diversity of training datasets, particularly regarding age, gender, and ethnicity, which could impact its ability to differentiate true pathology from normal variations in the Medicare population.
Icobrain offers fully automated volumetric and lesion quantification, which is clinically validated in peer-reviewed studies, providing objective and reproducible insights that can be more sensitive than visual rating alone, especially for subtle changes. It has demonstrated higher accuracy and faster processing compared to some traditional methods like FreeSurfer for certain brain structures.
Icobrain operates on a subscription-based pricing model, with costs typically determined by the number of analyses performed. While CPT-III codes 0865T and 0866T for brain MRI quantification, applicable to tools like Icobrain, became active in January 2024 to facilitate reimbursement, a Medicare Administrative Contractor has proposed denying coverage, citing insufficient evidence of clinical utility and validity.
Icobrain's efficacy is supported by numerous peer-reviewed studies demonstrating its ability to increase diagnostic accuracy, improve sensitivity in detecting disease activity, and reduce inter-reader variability. For example, studies have shown it significantly improves radiologists' accuracy in assessing ARIA and can reduce the duration of suboptimal treatment for multiple sclerosis patients.
Icobrain ensures patient data security and privacy by pseudonymizing incoming DICOM files according to HIPAA regulations, removing all personally identifiable information except for patient gender and birth year (transformed to YYYY-01-01). Data transfer is TLS encrypted (HTTPS), and icometrix maintains ISO27001 certification for its information security management system, continuously evaluating and strengthening its systems.
Suggest an Edit →
| Last Verified: 2026-04-20 | First Added: 2026-04-20